TW202039536A - 用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途 - Google Patents

用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途 Download PDF

Info

Publication number
TW202039536A
TW202039536A TW108145889A TW108145889A TW202039536A TW 202039536 A TW202039536 A TW 202039536A TW 108145889 A TW108145889 A TW 108145889A TW 108145889 A TW108145889 A TW 108145889A TW 202039536 A TW202039536 A TW 202039536A
Authority
TW
Taiwan
Prior art keywords
peptide
seq
variant
similarity
length
Prior art date
Application number
TW108145889A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆士 Ａ 瑞都斯維奇
麥可 巴畢奇
Original Assignee
美商拉比林免疫治療美國有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商拉比林免疫治療美國有限公司 filed Critical 美商拉比林免疫治療美國有限公司
Publication of TW202039536A publication Critical patent/TW202039536A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW108145889A 2018-12-13 2019-12-13 用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途 TW202039536A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779377P 2018-12-13 2018-12-13
US62/779,377 2018-12-13

Publications (1)

Publication Number Publication Date
TW202039536A true TW202039536A (zh) 2020-11-01

Family

ID=71077093

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108145889A TW202039536A (zh) 2018-12-13 2019-12-13 用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途

Country Status (11)

Country Link
US (1) US20220409709A1 (https=)
EP (1) EP3894432A4 (https=)
JP (2) JP2022513913A (https=)
KR (2) KR20260042221A (https=)
CN (1) CN113412275A (https=)
AU (1) AU2019397539B2 (https=)
CA (1) CA3123396A1 (https=)
IL (1) IL283933A (https=)
MX (1) MX2021007074A (https=)
TW (1) TW202039536A (https=)
WO (1) WO2020123964A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143868B (zh) * 2023-01-10 2025-10-21 合肥工业大学 一种能够增强咸味的多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
ATE536370T1 (de) * 2006-02-02 2011-12-15 Univ Alabama Res Found Nicht gespulte schutzregionen der pneumokokken- oberflächenproteine pspa und pspc
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
EP2607374A1 (en) * 2011-12-21 2013-06-26 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof
US20200190480A1 (en) * 2017-08-30 2020-06-18 Next Pharma Inc. ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING

Also Published As

Publication number Publication date
JP2022513913A (ja) 2022-02-09
IL283933A (en) 2021-07-29
KR102929753B1 (ko) 2026-02-24
AU2019397539A1 (en) 2021-07-15
EP3894432A4 (en) 2023-01-25
KR20260042221A (ko) 2026-03-30
CA3123396A1 (en) 2020-06-18
WO2020123964A1 (en) 2020-06-18
US20220409709A1 (en) 2022-12-29
JP2025072379A (ja) 2025-05-09
AU2019397539B2 (en) 2025-04-24
MX2021007074A (es) 2021-10-13
CN113412275A (zh) 2021-09-17
EP3894432A1 (en) 2021-10-20
KR20210131995A (ko) 2021-11-03

Similar Documents

Publication Publication Date Title
US6916476B1 (en) Ganglioslide-KLH conjugate vaccine plus QS-21
JP6359561B2 (ja) 高い炭水化物抗原密度を有するワクチン及び新規サポニンアジュバント
US20110165223A1 (en) Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
Ragupathi et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
BRPI1012890B1 (pt) Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit
US20160000894A1 (en) In vivo efficacy of ny-eso-1 plus adjuvant
US9737596B2 (en) Vaccine for the prevention of breast cancer recurrence
Song et al. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model
US20190030150A1 (en) Cancer Therapy
JP2024109648A (ja) ネオエピトープを標的とするワクチン
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
JP2025072379A (ja) がん免疫療法のためのラビリンチンベースのペプチドとその使用
JP6385280B2 (ja) 自家癌細胞ワクチン
US20190216907A1 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
ES2908071T3 (es) Composición de vacuna y usos de la misma
US20070190072A1 (en) In vivo efficacy of ny-eso-1 plus adjuvant
US20220023421A1 (en) Methods for eliciting selective humoral responses
BR112017021981B1 (pt) Composição de vacina e usos da mesma
BR122023010749B1 (pt) Saponina obi-821
BR112015016381B1 (pt) Vacina, e, composição farmacêutica
HK1213266B (zh) 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂